Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02411643 · ClinicalTrials.gov registry record · Early Phase 1
Molecular Effects of Topical Calcipotriene on Morphea
A Early Phase 1 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT02411643 is a Early Phase 1 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 2 participants.
The verdict
NCT02411643, a Early Phase 1 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study will look into how topical treatment with synthetic Vitamin D3, calcipotriene ointment, used as standard of care, works in patients with morphea. Skin biopsies of morphea lesions before and after treatment with topical calcipotriene 0.005% ointment will be analyzed for changes in RNA and protein. A skin biopsy of unaffected skin will also be obtained and used for a control. This is an initial study to look at the molecular effects of topical calcipotriene on human morphea-involved skin. This study will look at the differences between affected and unaffected skin. This study also will look at clinical outcomes in morphea patients and determine if there are any clinical predictors for improvement with the medication.
Interventions
- DRUG topical calcipotriene 0.005% ointment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02411643
The ClinicalTrials.gov registry entry for NCT02411643 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which topical calcipotriene 0.005% ointment is the first listed.
NCT02411643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02411643 about?
NCT02411643 is a clinical study titled "Molecular Effects of Topical Calcipotriene on Morphea". This study will look into how topical treatment with synthetic Vitamin D3, calcipotriene ointment, used as standard of care, works in patients with morphea. Skin biopsies of morphea lesions before and after treatment with topical calcipotriene 0.005% ointment will be analyzed for changes in RNA and ...
What is the current status of trial NCT02411643?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2015-03. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02411643?
The interventions under investigation include: topical calcipotriene 0.005% ointment (DRUG).
Who is sponsoring clinical trial NCT02411643?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.